Biocon has diversified and entered the digital therapeutic segment as part of its global strategy.
The Bengaluru-based company’s Malaysian subsidiary has collaborated with France-based healthcare solutions company Voluntis to develop and distribute a digital product for diabetic patients.
The product, called Insulia, provides automated insulin doserecommendations and messages for people with diabetes while enabling the healthcare team to remotely monitor progress.
It is an app which a healthcare practitioners need to prescribe using their dedicated web portal and sets up the treatment plan based on a person’s specific needs.
Once developed, Insulia will be offered to people with Type 2 diabetes using Biocon Biologics’ insulins in key global markets.
Going forward, by extending the Insulia platform to its range of insulin products, including Recombinant Human Insulin, Insulin Glargine and Insulin Aspart, Biocon Biologics plans to create a comprehensive digital therapeutics portfolio for patients.
This will be a part of the company’s larger global strategy where it will pair digital therapy with products, defining a new way of combination therapies.